about
Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese ratsPrieurianin Causes Weight Loss in Diet-Induced Obese Mice and Inhibits Adipogenesis in Cultured Preadipocytes.Treating obesity: a new target for prevention of coronary heart disease.Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat.Thermogenic effects of sibutramine and its metabolites.Pediatric obesity: parallels with addiction and treatment recommendationsNew drug policy in childhood obesity.Emerging drugs for eating disorder treatment.Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status.Epidemiology of Obesity and Pharmacologic Treatment Options.Effect of sibutramine HCl on cardiac hERG K+ channel.The anorexic agents, sibutramine and fenfluramine, depress GABA(B)-induced inhibitory postsynaptic potentials in rat mesencephalic dopaminergic cellsRecent advances in the pharmacological control of energy balance and body weight.Update on the pharmacotherapy of obesity.Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the ratInfluence of sibutramine on energy expenditure in African American women.Regulation of body weight and carcass composition by sibutramine in rats.Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial.Combined dietary and pharmacological weight management in obese hypopituitary patients.
P2860
Q24675513-12058F18-8ADF-401B-BE71-953358734D41Q30402685-DE674955-57D4-4BBE-961E-B2602D956EC7Q34314208-16C2708D-7D64-4102-8180-B7A1DA4C1F9EQ35026535-40C5E499-9200-4A00-AC57-CC955B9A3F36Q35028643-E4C398E5-68E7-4065-AFB8-E784AC2271FBQ35961441-78C98C0B-4CDA-4F34-BE38-17067BA0FF61Q36356847-37E7BFB7-014B-4FD3-A04C-D57B8009F37CQ36458423-3865CBFB-AE28-4DD6-921F-83B20E8B739CQ36673903-29641918-0D82-4C8D-A685-3B25BCF2541DQ38717129-D3279089-0063-4629-8C3A-7840CB38FFD4Q39941666-1CADB5FC-9570-41A8-A61F-89071DCC18E6Q41427028-C3CD5245-7C84-459F-83F1-0CCD73423F1AQ41611336-A5FBA47A-368D-4F7E-BBE1-03FF7D35243EQ41707222-D12FA5BB-78EE-4192-B72C-0E0DFF902402Q42057930-CA4F5CE5-251A-4806-BB33-91BB9209D0D1Q43594329-9BC2E509-F921-42D7-8BA1-9BBF969F193EQ43911362-1B634291-FB46-4D2D-8BBE-20E954F2C8D5Q44563283-ACC39D61-D84D-4685-A624-7870E3ACEA5AQ45188956-3DA6781A-A4F1-4A33-9516-0C5A327ACCDA
P2860
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Sibutramine: a novel new agent for obesity treatment.
@en
type
label
Sibutramine: a novel new agent for obesity treatment.
@en
prefLabel
Sibutramine: a novel new agent for obesity treatment.
@en
P2860
P1433
P1476
Sibutramine: a novel new agent for obesity treatment.
@en
P2093
P2860
P304
P356
10.1002/J.1550-8528.1995.TB00227.X
P478
P577
1995-11-01T00:00:00Z